Man Group
RUBY

Man Group’s Rubius Therapeutics, Inc RUBY Stock Holding History

Man Group’s Portfolio RUBY Stock Details RUBY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-31,143
Closed -$14K – 2331
2022
Q3 		$14K Buy
+31,143
New +$23.3K ﹤0.01% 1960
2022
Q2 		– Hold
0
– – – 1989

Other funds holding RUBY

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $18.9B AUM 27.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Man Group's RUBY Position: Q4 2022 in Review

Man Group sold out of Rubius Therapeutics, Inc (RUBY) in Q4 2022, closing a stake of 31,143 shares — an estimated $14K sold.

Man Group first reported a position in RUBY in Q3 2022 and held it in 1 quarter. The position peaked at $14K in Q3 2022. 42 funds tracked by Wall St. Rank hold RUBY as of Q4 2022.

  • Man Group reported no remaining Rubius Therapeutics, Inc position as of Q4 2022 after selling out during the quarter.
  • Man Group sold 31,143 Rubius Therapeutics, Inc shares in Q4 2022, an estimated $14K.
  • Man Group first reported a position in Rubius Therapeutics, Inc in Q3 2022 and held it in 1 quarter.
  • Man Group's Rubius Therapeutics, Inc position peaked at $14K in Q3 2022.
  • 42 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q4 2022.

Based on Man Group's 13F filing for Q4 2022, filed 14 Feb 2023.